Insulin glargine compared with Neutral Protamine Hagedorn insulin in the treatment of pregnant diabetics
- 1 January 2009
- journal article
- research article
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 22 (3), 249-253
- https://doi.org/10.1080/14767050802638170
Abstract
To compare maternal and neonatal outcomes of pregestational and gestational diabetics treated with insulin glargine versus Neutral Protamine Hagedorn (NPH) insulin. A retrospective cohort study examining outcomes from pregestational and gestational diabetics treated with either insulin regimen. Comparisons were made using the t-test for continuous data and the Chi-square or Fisher's exact test for categorical data. Fifty-two pregnant women treated with insulin glargine were compared with 60 pregnant women treated with NPH. No significant differences in rates of maternal complications were noted. No significant differences in neonatal outcomes for gestational diabetics were noted. Among pregestational diabetics treated with insulin glargine, significantly fewer macrosomic infants (relative risk [RR], 0.38; 95% confidence intervals (CI), 0.17-0.87; p = 0.04) and lower rates of neonatal hyperbilirubinemia (RR, 0.27; 95% CI, 0.07-0.98; p = 0.05) were noted when compared with those treated with NPH. There were no cases of neonatal hypoglycemia in pregestational diabetics treated with glargine; however, 25% of infants born to mothers treated with NPH experienced hypoglycemia (p = 0.01). No fetal anomalies or deaths were observed in either treatment group. Insulin glargine use during pregnancy is not associated with increased maternal or neonatal morbidity compared with NPH insulin. Among pregestational diabetics, insulin glargine use was associated with lower rates of macrosomia, neonatal hypoglycemia and neonatal hyperbilirubinemia.Keywords
This publication has 15 references indexed in Scilit:
- Survey of glargine use in 115 pregnant women with Type 1 diabetesDiabetic Medicine, 2008
- Use of insulin glargine during pregnancyActa Obstetricia et Gynecologica Scandinavica, 2007
- Successful use of insulin glargine during entire pregnancy until delivery in six Type 1 diabetic womenEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2007
- Use of insulin glargine during pregnancy: a case-control pilot studyBJOG: An International Journal of Obstetrics and Gynaecology, 2007
- Insulin therapy in pregnancy complicated by diabetes: are insulin analogs a new tool?Diabetes/Metabolism Research and Reviews, 2005
- Insulin AnaloguesNew England Journal of Medicine, 2005
- A review of basal insulinsDiabetic Medicine, 2003
- Evaluation of the Reproductive Toxicity and Embryotoxicity of Insulin Glargine (LANTUS) in Rats and RabbitsInternational Journal of Toxicology, 2002
- A united states national reference for fetal growthObstetrics & Gynecology, 1996
- Criteria for screening tests for gestational diabetesAmerican Journal of Obstetrics and Gynecology, 1982